Real-time · AI · Cross-signal
Discover the power of real-time signals plus AI
Every contract, funding round, exec hire, and M&A move on Boehringer Ingelheim — with verified, ICP-scored contact reveals (email + mobile) on demand.
Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.
Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration for Precision Cancer Treatment
Oct 09, 2024•over 1 year ago
Contract Type
partnership
Description
Boehringer Ingelheim and Circle Pharma have announced a new research collaboration and license agreement aimed at developing a first-in-class cyclin inhibitor to halt the growth of cancer cells. The collaboration focuses on targeting proteins involved in cell division regulation, offering hope for those with hard-to-treat cancers.
Related People
Suggested for you
Sign in to view contact details
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months